Kassberg Thomas Richard
SEC insider (Form 3/4/5 filer). CIK 0001303811. Director at Passage BIO, Inc. (PASG) and 1 other issuer. 6 reported Form 4/5 transactions since Sep 2024; latest on May 19, 2026. Located in PHILADELPHIA, PA.
Companies Kassberg Thomas Richard has filed insider reports for
- Passage BIO, Inc. (PASG): Director
- Ultragenyx Pharmaceutical Inc. (RARE): Officer, CBO & EVP
Kassberg Thomas Richard
CIK: 0001303811
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- May 19, 2026PASG
Passage BIO, Inc.
AwardDirectDirector Stock Option (right to buy)
10.5K shares- - May 28, 2025PASG
Passage BIO, Inc.
AwardDirectDirector Stock Option (right to buy)
143.8K shares- - Mar 3, 2025RARE
Ultragenyx Pharmaceutical Inc.
SaleDirect6K shares at avg. $42.10$254K - Mar 3, 2025RARE
Ultragenyx Pharmaceutical Inc.
Tax PaymentDirect508 shares at avg. $42.92$22K - Mar 1, 2025RARE
Ultragenyx Pharmaceutical Inc.
AwardDirect18.4K shares- - Sep 30, 2024PASG
Passage BIO, Inc.
AwardDirectEmployee Stock Option (right to buy)
174.1K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| May 19, 2026 |  PASG Passage BIO, Inc. | Award Director Stock Option (right to buy) | 10,539 | - | - | Direct |
| May 28, 2025 | PASG Passage BIO, Inc. | Award Director Stock Option (right to buy) | 143,789 | - | - | Direct |
| Mar 3, 2025 |  RARE Ultragenyx Pharmaceutical Inc. | Sale | 6,028 | $42.10 | $253,779 | Direct |
| Mar 3, 2025 | RARE Ultragenyx Pharmaceutical Inc. | Tax Payment | 508 | $42.92 | $21,803 | Direct |
| Mar 1, 2025 | RARE Ultragenyx Pharmaceutical Inc. | Award | 18,443 | - | - | Direct |
| Sep 30, 2024 | PASG Passage BIO, Inc. | Award Employee Stock Option (right to buy) | 174,139 | - | - | Direct |
1-6 of 6 transactions